Literature DB >> 34353347

Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy.

Chien-Yu Hsueh1,2,3,4, Chii-Yuan Huang2,3, Chia-Feng Yang5,6, Chia-Chen Chang7, Wei-Sheng Lin5, Hsiu-Lien Cheng2,8, Shang-Liang Wu9, Yen-Fu Cheng10,11,12,13,14, Dau-Ming Niu15,16.   

Abstract

BACKGROUND: Studies suggest that enzyme-replacement therapy (ERT) is crucial to the survival of patients with infantile-onset Pompe disease (IOPD). Hearing impairment (HI) is one of the clinical sequelae observed in long-term survivors. However, the benefits of early ERT for hearing outcomes have not yet been reported. This study aimed to investigate the impact of early ERT on IOPD patients.
METHODS: This retrospective longitudinal study recruited IOPD patients who were referred by newborn screening for confirmatory diagnosis based on our rapid diagnostic criteria and received early ERT treatment between January 1, 2010, and January 31, 2018. The hearing test battery included a tympanogram, otoacoustic emission, auditory brainstem evoked response (ABR), pure-tone audiometry or conditioned play audiometry.
RESULTS: Nineteen patients with IOPD were identified, 6 of whom had hearing impairment (HI); 1 had conductive HI, 2 had sensorineural HI (one had bilateral mild HI and one had mild HI in a single ear) and 1 had moderate mixed-type HI. Two patients failed the newborn screening test and had mild HI in the ABR. The mean age of the initial time to ERT was 11.05 ± 4.31 days, and the HI rate was 31.6% (6/19).
CONCLUSION: Our study is the largest cohort to show the characteristic hearing outcomes of IOPD patients after ERT. Early ERT within 2 weeks after birth may contribute to better hearing outcomes. Clinicians should be vigilant in testing for the hearing issues associated with IOPD and should intervene early if any HI is detected.
© 2021. The Author(s).

Entities:  

Keywords:  Congenital deafness; Enzyme-replacement therapy; Glycogen storage disorder; Hearing loss; Infantile-onset Pompe disease; Lysosomal storage disorder

Year:  2021        PMID: 34353347     DOI: 10.1186/s13023-021-01817-1

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  30 in total

1.  Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease.

Authors:  F Martiniuk; A Chen; A Mack; E Arvanitopoulos; Y Chen; W N Rom; W J Codd; B Hanna; P Alcabes; N Raben; P Plotz
Journal:  Am J Med Genet       Date:  1998-08-27

2.  Pompe's disease in Chinese and prenatal diagnosis by determination of alpha-glucosidase activity.

Authors:  C Y Lin; B Hwang; K J Hsiao; Y R Jin
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

3.  Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling.

Authors:  M G Ausems; J Verbiest; M P Hermans; M A Kroos; F A Beemer; J H Wokke; L A Sandkuijl; A J Reuser; A T van der Ploeg
Journal:  Eur J Hum Genet       Date:  1999-09       Impact factor: 4.246

4.  The frequency of lysosomal storage diseases in The Netherlands.

Authors:  B J Poorthuis; R A Wevers; W J Kleijer; J E Groener; J G de Jong; S van Weely; K E Niezen-Koning; O P van Diggelen
Journal:  Hum Genet       Date:  1999 Jul-Aug       Impact factor: 4.132

5.  Prevalence of lysosomal storage diseases in Portugal.

Authors:  Rui Pinto; Carla Caseiro; Manuela Lemos; Lurdes Lopes; Augusta Fontes; Helena Ribeiro; Eugénia Pinto; Elisabete Silva; Sónia Rocha; Ana Marcão; Isaura Ribeiro; Lúcia Lacerda; Gil Ribeiro; Olga Amaral; M C Sá Miranda
Journal:  Eur J Hum Genet       Date:  2004-02       Impact factor: 4.246

6.  Hearing loss in infantile Pompe's disease and determination of underlying pathology in the knockout mouse.

Authors:  Joep H J Kamphoven; Martijn M de Ruiter; Leon P F Winkel; Hannerieke M P Van den Hout; Jan Bijman; Chris I De Zeeuw; Hans L Hoeve; Bert A Van Zanten; Ans T Van der Ploeg; Arnold J J Reuser
Journal:  Neurobiol Dis       Date:  2004-06       Impact factor: 5.996

7.  Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.

Authors:  Yin-Hsiu Chien; Shu-Chuan Chiang; Xiaokui Kate Zhang; Joan Keutzer; Ni-Chung Lee; Ai-Chu Huang; Chun-An Chen; Mei-Hwan Wu; Pei-Hsin Huang; Fu-Jen Tsai; Yuan-Tsong Chen; Wuh-Liang Hwu
Journal:  Pediatrics       Date:  2008-06-02       Impact factor: 7.124

Review 8.  Pompe disease in infants and children.

Authors:  Priya Sunil Kishnani; R Rodney Howell
Journal:  J Pediatr       Date:  2004-05       Impact factor: 4.406

9.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

10.  Hearing in adults with Pompe disease.

Authors:  Nadine A M E van der Beek; Hans Verschuure; Arnold J J Reuser; Ans T van der Ploeg; Pieter A van Doorn; René M L Poublon
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

View more
  1 in total

1.  Early Blood Glucose Level Post-Admission Correlates with the Outcomes and Oxidative Stress in Neonatal Hypoxic-Ischemic Encephalopathy.

Authors:  Inn-Chi Lee; Jiann-Jou Yang; Ying-Ming Liou
Journal:  Antioxidants (Basel)       Date:  2021-12-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.